Sentynl Therapeutics Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited , has announced a strategic licensing agreement with PRG S&T, a Korean rare disease specialist, to acquire rights to investigational drug candidate Progerinin (SLC-D011) for treating Hutchinson-Gilford Progeria Syndrome. The agreement marks a significant expansion of Sentynl's rare disease portfolio, adding a second potential therapy for this ultra-rare genetic disorder.

Licensing Agreement Details

Under the terms of the agreement, Sentynl will collaborate with PRG S&T to advance clinical development of Progerinin, which has received orphan drug designation from the United States Food and Drug Administration. The company will acquire full rights to the molecule upon meeting certain milestones, with the program currently finalizing a Phase 2A clinical trial.

About Progerinin and Its Mechanism

Progerinin represents an investigational, orally active small-molecule drug designed to treat Hutchinson-Gilford Progeria Syndrome, a rare genetic disorder characterized by accelerated aging in children. The disease stems from mutations in the LMNA gene, which cause accumulation of progerin, an abnormal form of the lamin A protein that disrupts nuclear structure and leads to premature cellular aging.

The drug candidate works by inhibiting the interaction and harmful effects of progerin within cells, thereby improving nuclear integrity and reducing cellular damage. In mouse models of HGPS, progerinin demonstrated encouraging outcomes, increasing lifespan by 8–10 weeks and improving body weight in treated subjects compared to controls.

Clinical Trial Results in Animal Models

Leadership Perspectives

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, emphasized the acquisition's importance in growing their HGPS therapy portfolio. "Supporting patients in living healthy, fulfilled lives is core to what we do, and the agreement with PRG S&T directly furthers this mission by advancing orphan therapies for patients and families impacted by rare diseases," he stated.

Matt Heck, CEO of Sentynl, highlighted the commitment to translating research progress into real therapies. "This agreement, which will add Progerinin to our progeria portfolio, represents our commitment to translating that progress into another real therapy for children and families who need them," Heck commented.

Disease Background and Current Treatment Landscape

Hutchinson-Gilford Progeria Syndrome affects children with severe manifestations including failure to thrive, scleroderma-like skin, global lipodystrophy, alopecia, joint contractures, and accelerated atherosclerosis. Children with HGPS commonly die of heart disease by an average age of 14.50 years. Currently, Zokinvy® (lonafarnib) remains the only approved treatment for HGPS and certain processing-deficient Progeroid Laminopathies in the U.S., European Union, Great Britain, Israel, and Japan.

The Progeria Research Foundation, which funded foundational research leading to Progerinin's development, expressed support for the licensing agreement. Dr. Leslie Gordon, Medical Director at the foundation, noted their mission to find treatments and cure for Progeria, expressing gratitude for the collaborative efforts to improve patient lives.

Zydus Lifesciences Limited announced a significant regulatory milestone as its innovative drug Desidustat tablets received approval from China's National Medical Products Administration (NMPA) for treating renal anaemia. Following the approval, the company has confirmed the licensing arrangement with China Medical System Holdings Limited, representing a breakthrough in addressing the substantial unmet medical needs for Chronic Kidney Disease patients in China.

Drug Approval and Licensing Partnership

The NMPA approval covers Desidustat tablets for renal anaemia treatment in China, marking a crucial regulatory achievement for the innovative therapy. CMS International Development and Management Limited, a wholly-owned subsidiary of China Medical System Holdings Limited, obtained an exclusive license for the drug from Zydus in 2020. The licensing arrangement has now been activated following the regulatory approval.

Clinical Innovation and Mechanism

Desidustat tablets represent a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) specifically designed for treating anaemia in Chronic Kidney Disease patients. The drug addresses a critical medical challenge where impaired kidneys reduce Erythropoietin production, leading to anaemia development. HIF-PHI promotes erythropoiesis by increasing endogenous erythropoietin and reducing hepcidin, thereby improving iron availability.

The China Phase III clinical trial demonstrated positive results, meeting its primary efficacy endpoint. Extension study results showed the drug could maintain haemoglobin levels within target ranges over long-term treatment with acceptable safety profiles, while significantly reducing hepcidin levels and improving iron metabolism disorders.

Market Opportunity and Patient Impact

China presents a substantial market opportunity with significant unmet medical needs in CKD anaemia treatment. The oral administration of Desidustat is expected to improve patient treatment compliance and address critical gaps in current therapy options.

Indian Market Success

Desidustat is discovered, developed and marketed by Zydus in India under the brand name Oxemia™. The drug has demonstrated significant clinical success, with more than 1 lakh CKD patients in India successfully treated since its launch in 2022.

Management Commentary

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, commented on the development: "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally. We are happy to partner with CMS and are confident that this will expand access to patients suffering from Chronic Kidney Disease across Greater China."

The approval represents a significant milestone in Zydus' mission to transform lives through pathbreaking discoveries and expand access to innovative healthcare solutions globally. With CMS's proven commercialization capabilities and extensive networks in specialty therapeutic fields, the partnership positions Desidustat for successful market penetration across Greater China.